

MAURICIO BUROTTO, MD

1. CONTACT INFORMATION

Manzano 343, Recoleta, Santiago Oficina 401, 402, 403 y 414

mauricioburotto@gmail.com

Phone: +569-54240753

2. CURRENT POSITION

Medical Director Centro de Estudios Clinicos Bradford Hill

3. PREVIOUS POSITIONS:

2015-2017

Director of the Medical Oncology Department Clinica Alemana de Santiago.

2015-2018

Academic and Scientific Delegate of Oncology, Clinica Alemana de Santiago.

2009-2011

Medical Oncology Staff at Pontificia Universidad Catolica de Chile.
Santiago, Chile

2015-2017

Medical Oncology Director at Clinica Alemana de Santiago
Santiago Chile

4. RELEVANT ACADEMIC BACKGROUND:

2013-2014

Fellowship in Pulmonary Oncology
National Cancer Institute
National Institutes of Health
Bethesda, MD

2011- 2013

Medical Oncology Fellowship
National Cancer Institute
National Institutes of Health
Bethesda, MD

2006-2009

Hematology and Oncology Fellowship

Pontificia Universidad Católica de Chile.
Santiago, Chile

2003-2006
Internal Medicine Residency
Pontificia Universidad Católica de Chile
Santiago, Chile

1995-2002
Medicine
Universidad de Concepcion
Concepcion, Chile

5. ACADEMIC POSITIONS

2009-2011 Academic Instructor, Hematology Oncology.
Pontificia Universidad Católica de Chile
Santiago, Chile

6. PROFESSIONAL HONORS

2014 Conquer Cancer Foundation of ASCO Merit Award: Abstract #427: Phase II clinical trial of bevacizumab plus ixabepilone in renal cell carcinoma.
Genitourinary Cancer Symposium ASCO.

7. PUBLICATIONS

1. Patil PD, **Burotto M**, Velcheti V. *Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead* Expert Rev Mol Diagn. 2018 Mar;18(3):297-305. doi: 10.1080/14737159.2018.1440209.Epub 2018 Feb 15.
2. Blagoev KB, Wilkerson J, **Burotto M**, Kim C, Espinal-Domínguez E, García-Alfonso P, Alimchandani M, Miettinen M, Blanco-Codesido M, Fojo T; *Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status*; PLoS One. 2017 Oct 5;12(10): e0175484
3. O'Sullivan Coyne G, Burotto M; *MABp1 for the treatment of colorectal cancer*; Expert Opin Biol Ther. 2017 Sep;17(9):1155-1161
4. Fernandez-Bussy S, Labarca G, Vial MR, Soto R, Mehta HJ, Jantz M, Maji A, **Burotto M**; *Recurrent Respiratory Papillomatosis and Bevacizumab Treatment*. Am J Respir Crit Care Med. 2017 Oct 2. [

5. **Burotto M**, Ederly M, Velarde M, Balasubramaniam S, Drabkin H, Gormaz JG, O'Sullivan C, Madan R, Fojo T; *A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma*; *Oncologist* 2017 Aug; 22(8):888-e84.
6. O'Sullivan CC, Lindenberg M, Bryla C, Patronas N, Peer CJ, Amiri-Kordestani L, Davarpanah N, Gonzalez EM, **Burotto M**, Choyke P, Steinberg SM, Liewehr DJ, Figg WD, Fojo T, Balasubramaniam S; *Bates SE. AN1005 for breast cancer brain metastasis: correlation between ¹⁸F-FLT-PET after first cycle and MRI in response assessment*. *Breast Cancer Res Treat*. 2016 Nov;160 (1):51-59.
7. Fernandez-Bussy S, Labarca G, Pires Y, Caviedes I, **Burotto M**; *Molecular Testing of EGFR, EGFR Resistance Mutation, ALK and ROS Achieved by EBUS-TBNA in Chile*. *Arch Bronconeumol*. 2016 Nov 5: S0300-2896(16)30250-2
8. **Burotto M**, Berkovits A, Dunleavy K; *Double hit lymphoma: from biology to therapeutic implications*. *Expert Rev Hematol*. 2016 Jul; 9 (7):669-78
9. Chiou VL, **Burotto M**; *Reply to A. Wong et al*. *J Clin Oncol*. 2016 May 1; 34(13):1562-3
10. **Burotto M**, Prasad, V; *Emphasizing Unique Strengths and Eliminating Redundancy for Research in Low and Middle Income Countries: Lessons from a South American Country*; *Cancer*. 2015 Aug 15; 121(16): 2668-7
11. Chiou VL, **Burotto M**; *Pseudoprogression and Immune-Related Response in Solid Tumors*; *J Clin Oncol* 2015 Aug 10 JCO.2015.61.6870
12. Prasad V, Kim C, **Burotto M**, Vandross A; *The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses*. *JAMA Intern Med*. 2015 Aug 1; 175 (8): 1389-98.
13. **Burotto M**, Ederly M, Poruchynsky M, Velarde M, Wilkerson J, Kotz H, Merino M, Bates SA, Balasubramaniam S, Fojo T; *Phase II clinical trial of ixabepilone in metastatic cervical carcinoma*; *Oncologist*. 2015 Jul; 20 (7):725-6
14. **Burotto M**, Manasanch E, Wilkerson J, Fojo T; *Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials Supports the Approval of Gefitinib by the US FDA*; *Oncologist*. 2015 Apr;20(4):400-10
15. **Burotto M**, Prasad V, Fojo T; *Non-inferiority trials: why oncologists must remain wary*. *Lancet Oncol*. 2015 Apr;16(4):364-6
16. Poruchynsky MS, Komlodi-Pasztor E, Trostel S, Wilkerson J, Pommier Y, Guha u, Zhang X, Kumar Maity T, Robey R, **Burotto M**, Fojo T; *Microtubule-Targeting Agents Augment the Toxicity of DNA Damaging Agents by Disrupting Intracellular Trafficking of DNA Repair Proteins*; Submitted to Proceedings of the National Academy of Sciences of the United States of America (PNAS) 2015 Feb 3;112(5):1571-6

17. **Burotto M**, Tajeja N, Rosenberg A, Mahalingam S, Quezado M, Velarde M, Edgerly M, Fojo T; *Brain Metastasis in Patients with Adrenocortical Carcinoma. A Clinical Series*; Journal of Clinical Endocrinology and Metabolism 2015 Feb;100(2):331-6
18. **Burotto M**, O'Sullivan C, Ali A; *Class Act: safety comparison of approved Tyrosine Kinase Inhibitors for Non-small cell Lung carcinoma*; Expert Opinion in Drug Safety 2015 Jan;14(1):97-110
19. **Burotto M**, Nishith Singh, Christopher R. Heery, James L. Gulley, Ravi A. Madan; *Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer*; Research Topic "Advances in Combination Tumor Immunotherapy" Frontiers in Oncology 2014 Dec 12;4:351
20. **Burotto M**, Thomas S, Subramaniam D, Giaccone G, Rajan A; *Review Article Biomarkers in Early-Stage Non-Small Cell Lung Cancer: Current Concepts and Future Directions*. Journal of Thoracic Oncology 2014 Nov;9(11):1609-17
21. **Burotto M**, Wilkerson J, Stein W, Motzer R, Bates S, Fojo T; *Continuing a cancer treatment despite tumor growth may be valuable. Sunitinib in renal cell carcinoma as example*; PLOS one 2014 5;9(5):e96316. doi: 10.1371/journal.pone.0096316. eCollection 2014
22. **Burotto M**, Chiou V, Lee JM, Kohn E; *The MAPK pathway across different malignancies: A new perspective*. Cancer 2014 Nov 15;120(22):3446-56
23. O'Sullivan C, **Burotto M**; *Clinical Experience with Ramucirumab: Outcomes in Breast Cancer*. Expert Opinion on Biological Therapy 2014 Sep;14(9):1351-60
24. **Burotto M**, Szabo E; *PPARγ in Head and Neck Cancer Prevention*; Oral Oncology, 2014 Jan 13. pii: S1368-8375(13)00808
25. **Burotto M**, Stetler-Stevenson M, Arons E, Zhou H, Wilson W, Kreitman RJ; *Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia*; Clin Cancer Res; 2013 Nov 15;19(22):6313-21
26. Rahma O, **Burotto M**, Do Canto L, Germano A, Haddad B, Marshall J; *Striking Similarities in Genetic Aberrations Between a Primary Rectal Tumor and its Lung Recurrence After 19 Years of Disease-Free Survival*; World J Gastrointest Oncol; 2013 Nov 15;5(11):198-203
27. **Burotto M**, Fojo AT; *Acetyl-L-carnitine and prevention of chemotherapy-induced peripheral neuropathy: can anything work?*; Oncologist. 2013;18(11):1151-2
28. **Burotto M**, Hartley ML, Marshall JL, Pishvaian MJ; *Future Targeted Agents in Metastatic Colorectal Cancer*; Colorectal Cancer 2012;1(5):433-443.
29. Gabrielli, L, Cordova S, Fasce F, **Burotto M**, Zalaquet, R; *Heart Disease by Carcinoid*; Revista Chilena de Cardiología 2011;30(3):240-242

30. Nazal L, Riquelme A, Solís N, Pizarro M, Escalona A, **Burotto M**, Méndez JI, Saint-Jean C, Concha MJ, Giovanni S, Awruch D, Morales A, Baudrand R, Carrasco G, Domínguez MA, Padilla O, Espinoza M, Miquel JF, Nervi F, Arrese M; *Hypoadiponectinemia and its association with liver fibrosis in morbidly obese patients*; *Obes Surg* 2010 Oct;20(10):1400-7.
31. **Burotto P M**, Bertín C-M P, Galindo A H, Garrido S M, Melgoza P G, Nervi N B, Ramírez V P, Ocqueteau T M, Besa de C P, García V V, Jara A V, Alvarez J E, Betancur B M, Rivera L M, Alvarez Z M; *Umbilical cord hematopoietic precursors transplantation. Report of five patients*; *Rev Med Chil.* 2009 Aug;137(8):1054-60.
32. **Burotto M**, Gabrielli L, Crossley N; [*Critical appraisal: Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Prandoni P, Carnovali M, Marchiori A, Galilei investigators. Arch Intern Med* 2004; 164: 1077-83]; *Revista Medica Chilena* 2004 Sep;132(9):1140-3.
33. Acevedo CG, Carrasco G, **Burotto M**, Rojas S, Bravo I; *Ethanol inhibits L-arginine uptake and enhances NO formation in human placenta*; *Life Sci.* 2001 May 18; 68(26): 2893-903.

8. CLINICAL PROTOCOLS

Universidad de Chile and Clínica Alemana of Santiago
 International Center of Excellence Pfizer Chile
 Genetic study and following of Renal Tumor in Chile
Co-Investigator: Mauricio Burotto Pichun, MD.

Clínica Alemana of Santiago
 FONDECYT 2015 N°11150999; International Registration: ISRCTN69560410. April 2016.
 Pharmacological Preconditioning with DHA Plus Carvedilol to Prevent Cardiotoxicity Associated to Anthracycline Chemotherapy in Patients with Breast Cancer.
Co-investigator: Mauricio Burotto Pichun, MD.

Clinica Alemana of Santiago (Recruiting Site)
 Merck Sharp & Dohme Corp.
 A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer – (KEYNOTE-355)
Principal Investigador site: Mauricio Burotto Pichun, MD.

Clinica Alemana of Santiago (Recruiting Site)
 F. Hoffmann-La Roche Ltd.
 A Phase III, multicenter, randomized, placebo-controlled, double blind study of Atezolizumab (Anti-PD-L1 antibody) in combination with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with untreated locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-based combinations.
Principal Investigador site: Mauricio Burotto Pichun, MD.

National Cancer Institute, NIH

Phase II Study of Axitinib (AG-013736) with Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma.

Principal Investigator: Tito Fojo M.D, Ph.D. **NCT01967576**

Lead Investigator: Mauricio Burotto Pichun, MD.

National Cancer Institute, NIH

A Pilot Study of Metformin in Patients with a Diagnosis of Li-Fraumeni Syndrome

Principal Investigator: Tito Fojo M.D, Ph.D. **NCT01981525**

Associate Investigator: Mauricio Burotto Pichun, MD.

National Cancer Institute, NIH

A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma. **NCT00923130**

Principal Investigator: Tito Fojo M.D, Ph.D.

Lead Investigator: Mauricio Burotto Pichun, MD.

National Cancer Institute, NIH

A Phase I, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies. **NCT00923520**

Principal Investigator: Susan Bates, M.D

Associate Investigator: Mauricio Burotto Pichun, MD.

National Cancer Institute, NIH

A Phase I Study of Belinostat in Combination with Cisplatin and Etoposide in Adults with a Focus on Small Cell Lung Cancer and other Cancers of Neuroendocrine Origin. **NCT00926640**

Principal Investigator: Susan Bates, M.D

Associate Investigator: Mauricio Burotto Pichun, MD.

National Cancer Institute, NIH

A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination with Trastuzumab in Breast Cancer Subjects with Brain Metastases. **NCT01480583**

Principal Investigator: Susan Bates, M.

Associate Investigator: Mauricio Burotto Pichun, MD.

9. ABSTRACTS-POSTER PRESENTATIONS

1. 2015 ASCO

Single institution experience with 75 mg dose of erlotinib in Latin American patients with mutated metastatic non-small cell lung cancer. Osvaldo Rudy Aren, Ricardo Silva, Humberto Cerda, Jorge M Arancibia, Carlos Rojas, Mauricio Reyes, Rodrigo Andres Ascui, Patricia Banchemo, **Mauricio Burotto**

2. 2015 ASCO
Effect of Treatment on the Regression and Growth Rates of Thymic Epithelial Tumors (TETs). **Mauricio Burotto**, Anish Thomas, Julia Wilkerson, Raffit Hassan, Tito Fojo, Giuseppe Giaccone, Arun Rajan
3. 2015 12th International Congress on Targeted Anticancer Therapies (TAT)
ANG-1005 in Patients with Brain Metastases from Breast Cancer: Correlative Imaging with 18F-FLT-PET/CT. Susan Bates, Maria Lindenberg, **Mauricio Burotto**, Christine Bryla, Nicholas Patronas, Laleh Amiri-Kordestani, Tito Fojo, Sanjeeve Balasubramanian, Peter Choyke
4. 2015 Genitourinary Malignancies GU ASCO
Phase II clinical trial of axitinib in metastatic pheochromocytomas and paragangliomas (P/PG): Preliminary results. **Mauricio Burotto**, Maureen Edgerly, Margarita Velarde, Susan Elaine Bates, Roland Daerr, Karen Adams, Karel Pacak, Tito Fojo
5. 2014 ASCO
Phase 2 clinical trial of ixabepilone in metastatic cervical carcinoma
Mauricio Burotto, Maureen Edgerly, Margarita Velarde, Herbert Kotz, Susan Bates, Sanjeeve Balasubramanian, Tito Fojo
6. 2014 ASCO
Effect of chemotherapy on the progress in colorectal cancer survival in the past two decades. Irfan Jawed, Julia Wilkerson, **Mauricio Burotto**, Austin G. Duffy, Antonio Tito Fojo
7. 2014 AACR
Microtubule-targeting agents (MTAs) disrupt intracellular trafficking of DNA repair proteins and augment the toxicity of DNA damaging agents (DDAs)
Marianne S. Poruchynsky, Edina Komlodi-Pasztor, Julia Wilkerson, Shana Trostel, **Mauricio Burotto**, Tito Fojo.
8. 2014 12th International Congress on Targeted Anticancer Therapies (TAT)
Emergence of KRAS mutations does not explain acquired resistance to panitumumab in second-line treatment of metastatic colorectal cancer (mCRC).
Mauricio Burotto, Julia Wilkerson, Montserrat Blanco-Codesido, Edward Espinal-Domínguez, Pilar García-Alfonso, Meghna Alimchandani, David Kleinier, Markku Miettinen, Krastan Blagoev, Tito Fojo
9. 2014 Genitourinary Malignancies GU ASCO
Phase 2 Clinical Trial of Bevacizumab and Ixabepilone in Renal Cell Carcinoma (RCC). Preliminary results.
Mauricio Burotto, Nicolas Acquavella, Maureen Edgerly, Sanjeeve Balasubramanian, Margarita Velarde, Susan Bates, Tito Fojo
10. 2013 ASCO

J Clin Oncol 31, 2013 (suppl; abstr 4585) Do we really have so many options in renal cell carcinoma (RCC)? Analysis of the sunitinib registration trial suggests the best second line therapy following first line sunitinib may be continued sunitinib.

Mauricio Burotto, Julia Wilkerson, Wilfred Stein, Robert Motzer, Susan Bates and Tito Fojo

11. 2013 ASCO

J Clin Oncol 31, 2013 (suppl; abstr e14592) Relationship of the emergence of KRAS mutations and resistance to panitumumab in second-line treatment of colorectal cancer (CRC).

Krastan B. Blagoev, **Mauricio Burotto**, Julia Wilkerson, Montserrat Blanco-Codesido, Edward Espinal Dominguez, Pilar Garcia-Alfonso, Antonio Tito Fojo

12. 2012 ASH

Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox

Robert J. Kreitman, Evgeny Arons, Jeffrey Sapolsky, Laura Roth, Hong Zhou, **Mauricio Burotto**, Daphna Katz¹, Maryalice Stetler-Stevenson, Wyndham H. Wilson, Mark Raffeld, David Fitzgerald, Ji Fei, Ramy Ibrahim, and Ira Pastan. National Cancer Institute Bethesda, MD.

13. 2008 Chilean Congress of Cancerology. Viña Del Mar Chile.

Neuroendocrine advanced colorectal tumor, a case with chemotherapy response. **Burotto M**, Alvarez Manuel, Galindo Héctor, Garrido Marcelo

10. ORAL PRESENTATIONS

2017 Chilean Urology Congress. Symposium. Immuno-oncology

2017 Molecular Pathology Course Clínica Alemana de Santiago, Chile
Immuno-Oncology, Diagnostic and Treatment Challenges

2017 XXIII Dermatology Course CAS 2017. Clínica Alemana de Santiago, Chile
Melanoma Management, New Paradigms

2017 III Lung Cancer Course. Clínica Alemana de Santiago, Chile
Systemic therapy in Thoracic Non-Lung Cancer Malignancies

2017 III Immunology-Oncology Summit Bristol-Myers Squibb. Lima, Peru
Chairman of the Basic Immunology section

2016 IMVIGOR 130 Investigator Meeting. Santiago, Chile
Phase II IMvigor210 data

2016 III Meeting of Nursing Oncology at Clínica Alemana de Santiago, Transition of Chemotherapy to Therapy Target.

2016 III Spring meeting. Chilean Society of Respiratory Diseases (SER) Tumor Immunotherapy. Role in the cancer treatment.

2016 April General Clinical Reunion CAS. Cancer Investigation, NIH-NCI experience.

2016 International Symposium of Evaluation and Manage of Patients with high oncological risk. UDD-CAS, Santiago, Chile. Feocromocitoma/paraganglioma and hereditary syndromes.

2016 Genomic and Precision Medicine Symposium. UDD-CAS. Santiago, Chile. Precision Medicine in Oncology: clinical perspectives and challenges

2016 II Immunology-Oncology Summit Bristol-Myers Squibb. Viña del Mar, Chile. Chairman of the 2 days event.

2015 2nd Annual Meeting of the Chilean Society of Medical Oncology
Cancer Research. My Personal Experience

2015 2nd Annual Meeting of the Chilean Society of Medical Oncology
Molecular Biology of Kidney Cancer

2015 I International Symposium of Suprarenal Endocrinology and Oncology. Santiago, Chile
Clinical Management of Malignant Pheocromocytoma.

2015 Central America Chapter Scientific Meeting ACP. Ciudad de Panama. Panama
Immunotherapy and Cancer Where are we going?

2015 Central America Chapter Scientific Meeting ACP. Ciudad de Panama. Panama
Prevention and Screening in Cancer

2015 Central America Chapter Scientific Meeting ACP. Ciudad de Panama. Panama
Oncologic Emergencies

2014 The Future In Oncology: The Next 10 years. Santiago, Chile
Tyrosine Kinase Inhibitors: Promises and Challenges

2014 The Future In Oncology: The Next 10 years. Santiago, Chile
What is the future in the evaluation of response and drug resistance in cancer therapies?

2014 SLAURO Viña Del Mar, Chile
Growth rate constant in tumors as a predictive factor for overall survival

2014 SLAURO Viña Del Mar, Chile
Sequencing therapies in metastatic renal cell carcinomas

2014 Demystifying Medicine 2014. National Institutes of Health Bethesda, MD, USA
Drug Resistance in Cancer: Mechanism and Management

2013 I Simposio de Actualización en Oncología. Santiago, Chile

Conferencia: investigación en cáncer: ¿Cómo integrar las partes en una era de conocimientos fragmentados?

2013 Joint Branch Meeting Presentation. National Cancer Institute. Bethesda, MD, USA
New Concepts in Tumor Progression and Drug Efficacy

2011 Primer Congreso Nacional Multidisciplinario para Medicos Residentes de Oncologia.
Santiago, Chile
EGFR como target en el tratamiento de cancer de pulmon.

2008 Congreso Chileno de Cancerologia. Viña Del Mar, Chile.
Sesion Plenaria: Trasplante de cordón umbilical en adultos con neoplasias hematologicas en Chile.
Experiencia inicial.

Burotto M, Nervi B, Bertín P, Ramírez P, Ocqueteau M, Alvarez M.

11. ACADEMIC SPECIFIC TRAINING

01/2013 NCI/CCR Statistical Analysis of Research Data Course
07/2014 Summer Curriculum in Principles and Practice in Cancer Prevention
08/2014 Summer Curriculum in Molecular Prevention
09/2014-11/2014 Practical Bioinformatics [BIOF429]

12. PROFESSIONAL SOCIETIES

2015- up to date: International Association of Study of Lung Cancer (IASLC)
2015- up to date: Sociedad Chilena de Oncologia Medica (SCHOM)
2011- up to date: American Society of Clinical Oncology (ASCO)
2011- up to date: American Society of Hematology (ASH)
2010- up to date: Sociedad Chilena de Cancerologia
2009-up to date: American College of Physicians (ACP)
2008- up to date: American Association of Cancer Research (AACR)

13. COMMITTEE RESPONSIBILITIES

2016- up to date. National Cardio-Oncology Committee
2013- 2014 to date. QA Pharmacy Committee National Institutes of Health

14. BOOK CHAPTERS

Burotto M, Read S, Gea-Banacloche JC; Infectious Complications in Oncology; JL Gulley, C Allegra;
The Bethesda Handbook of Clinical Oncology; Lippincott Williams & Wilkins; Philadelphia.

Burotto M, Fojo T. Oncologic Emergencies; M Boyliadzis, P Lebowitz, D Kohler, T Fojo; Hematology
– Oncology Therapy; McGrawHill.

15. EDITORIAL BOARDS

2016-up to date

Journal of Thoracic Oncology

2016 to 2017

Seminars in Oncology

2013 to 2014

NIH Fellows Editorial Board (FEB)

16. REVIEWER OF SPECIFIC JOURNALS

Cancer Research

Oncology & Hematology Review

Cancer

World Journal of Surgical Oncology

Annals of Clinical Pathology

Revista Medica de Chile

Biomarkers in Medicine

17. LANGUAGES

Spanish: Maternal Language

English: Advance Level